Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.
Saved in:
| Title: | Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer. |
|---|---|
| Authors: | Gengwei Huo1,2,3,4, Wenjie Liu1,2,3,4, Peng Chen1,2,3,4 chenpengdoc@sina.com |
| Source: | Journal of Gynecologic Oncology. Sep2024, Vol. 35 Issue 5, p1-12. 12p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
